![]() |
STUART, Fla., Oct. 16, 2026 /PRNewswire/ — Health In Tech, Inc. (Nasdaq: HIT) (“Health In Tech” or the “Company”) will host its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) on Tuesday, November 10, 2026, at 10:00 AM ET via live virtual webcast.
At the 2026 Annual Meeting, holders of Company stock as of the close of business on September 18, 2026 (the “Record Date”) will be able to vote their shares electronically and submit questions during the meeting.
To participate in the 2026 Annual Meeting, such stockholders as of the Record Date should visit www.cleartrustonline.com/HIT. Guests may also access the 2026 Annual Meeting in listen-only mode. No control number is required for guests.
A replay of the webcast will be accessible on the Company’s website at https://healthintech.investorroom.com/Events.
About Health In Tech
Health In Tech, Inc. (Nasdaq: HIT) is an AI-enabled InsurTech platform company, which offers a marketplace that aims to improve processes in the health insurance industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, managing general underwriters (“MGUs”) and third-party administrators (“TPAs”). Health In Tech’s platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for employers, providing functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims administration and reporting integration.
Investor Contact:
Health In Tech Investor Relations
[email protected]
ข่าวที่เกี่ยวข้อง
- World Young Scientist Summit 2026 Opens in Wenzhou, Zhejiang
- The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
- Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
- 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer

